v3.26.1
Segment Information
6 Months Ended
Jun. 30, 2026
Segment Information  
Segment Information

15. Segment Information

The Company’s operations are comprised of three reportable segments:

Diagnostics, which consists of TRUFORMA®, VETGuardian®, and TRUVIEW® products;

Therapeutic Devices, which consists of Assisi®, PulseVet®, and VETIGEL® products; and

Developmental Services, which consists of contract manufacturing and engineering services, including Cell-Guardian.

The Company’s Chief Operating Decision Maker (CODM) is its Chief Executive Officer who has ultimate responsibility for enterprise decisions. Segment information is used by the CODM to evaluate financial performance and to make strategic decisions related to resource allocation and operational focus across the segments. The CODM does not assess individual expense line items beyond cost of goods sold, nor does the CODM evaluate additional financial measures or allocate assets at the segment level.

Although our reportable segments provide similar products, each one is managed separately to better align with the Company’s customers and distribution / development partners. The CODM determines resource allocation for, and monitors performance of, the consolidated enterprise, which includes the Diagnostics, Therapeutic Devices and Development Services segments. The CODM relies on internal segment reporting that analyzes results on certain key performance indicators, namely, revenues, cost of goods sold, and gross profit. Cost of goods sold is the only significant expense evaluated at the segment level, as it is critical for assessing gross profit and segment performance. Costs below gross profit, such as operating expenses, are not allocated to the segments, nor are asset groupings, except for the purpose of periodic impairment analysis.

The following is a reconciliation of consolidated revenue, cost of revenue, and gross profit amongst our reportable segments for the three and six months ended June 30, 2026 and 2025:

Three Months Ended June 30, 

  ​ ​ ​

Diagnostics

  ​ ​ ​

Therapeutic
Devices

  ​ ​ ​

Development
Services

  ​ ​ ​

Consolidated

2026

2025

2026

2025

2026

2025

2026

2025

Net revenue

$

1,385

$

781

$

6,754

$

6,183

$

1,373

$

-

$

9,512

$

6,964

Cost of revenue

 

630

589

2,237

1,709

604

-

 

3,471

  ​

 

2,298

Gross profit

$

755

$

192

$

4,517

$

4,474

$

769

$

-

$

6,041

$

4,666

Six Months Ended June 30, 

  ​ ​ ​

Diagnostics

  ​ ​ ​

Therapeutic
Devices

  ​ ​ ​

Development
Services

  ​ ​ ​

Consolidated

2026

2025

2026

2025

2026

2025

2026

2025

Net revenue

$

2,351

$

1,340

$

12,575

$

12,124

$

3,385

$

-

$

18,311

$

13,464

Cost of revenue

 

1,217

1,146

4,031

3,245

1,538

-

 

6,786

  ​

 

4,391

Gross profit

$

1,134

$

194

$

8,544

$

8,879

$

1,847

$

-

$

11,525

$

9,073

For the three months ended June 30, 2026, revenue from external customers in the U.S. was $7,864 and from customers in foreign countries was $1,648, compared to $5,561 and $1,403, respectively, for the same period in 2025. For the six months ended June 30, 2026, revenue from external customers in the U.S. was $15,247 and from customers in foreign countries was $3,064, compared to $10,614 and $2,850, respectively, for the same period in 2025.